IO Biotech, Inc. (IOBT): Price and Financial Metrics

IO Biotech, Inc. (IOBT): $4.55

-0.30 (-6.19%)

POWR Rating

Component Grades













Add IOBT to Watchlist
Sign Up

Industry: Biotech



in industry

IOBT Stock Price Chart Interactive Chart >

Price chart for IOBT

IOBT Price/Volume Stats

Current price $4.55 52-week high $17.88
Prev. close $4.85 52-week low $3.56
Day low $4.38 Volume 37,900
Day high $4.88 Avg. volume 33,400
50-day MA $6.52 Dividend yield N/A
200-day MA $0.00 Market Cap 131.11M

IO Biotech, Inc. (IOBT) Company Bio

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.

IOBT Latest News Stream

Event/Time News Detail
Loading, please wait...

IOBT Latest Social Stream

Loading social stream, please wait...

View Full IOBT Social Stream

Latest IOBT News From Around the Web

Below are the latest news stories about IO Biotech Inc that investors may wish to consider to help them evaluate IOBT as an investment opportunity.

What Kind Of Investors Own Most Of IO Biotech, Inc. (NASDAQ:IOBT)?

If you want to know who really controls IO Biotech, Inc. ( NASDAQ:IOBT ), then you'll have to look at the makeup of its...

Yahoo | February 7, 2022

Nasdaq’s European Markets Delivered Record Year in 2021

- Solidified Nasdaq position as the leading European listings hub with 219 new equity listings, including a record number of 174 initial public offerings (IPOs), raising a total of EUR 13.4 billion- Retail inflow and large interest in SME trading spurred all-time high levels in equity and derivative trading- Continued to lead in ESG with venture investment in and new product launches STOCKHOLM, Sweden, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that Nasdaq

Yahoo | January 21, 2022

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody

Intrado Digital Media | December 9, 2021

IO Biotech collaborates with Merck to evaluate IO102-IO103 + Keytruda in three tumor types

No summary available.

Seeking Alpha | December 6, 2021

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor typesNEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that it has entered into a third clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and C

Yahoo | December 6, 2021

Read More 'IOBT' Stories Here

IOBT Price Returns

1-mo -38.18%
3-mo -37.84%
6-mo -47.94%
1-year N/A
3-year N/A
5-year N/A
YTD -28.91%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8282 seconds.